New advances in the fight against the most common form of lung cancer

New advances in the fight against the most common form of lung cancer

9.04.2025 - Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients show molecular alterations in the ALK gene involved in cell multiplication. The use of inhibitors against this oncogene - one of the most effective strategies against this type of cancer - has benefited many patients.

Pathology Researcher Keith Kerr Receives 2025 Heine H. Hansen Award - ILCN.org (ILCN/WCLC)

World-renowned non-small cell lung cancer (NSCLC) expert Keith Kerr, BSc, MB, ChB, told attendees of the European Lung Cancer Congress (ELCC) 2025 that the historic disconnect between lung cancer pathologists and clinicians has narrowed, with advances in precision medicine and artificial intelligence (AI) leading to novel ways of integrating insights from pathology classification into clinical decision-making. Keith Kerr, BSc, MB, ChB Dr. Kerr,…

FDA clears CureVac's IND application for Phase I lung cancer trial

The FDA has granted clearance to CureVac's IND for the open-label Phase I trial of CVHNLC in individuals with sqNSCLC.The post FDA clears CureVac’s IND application for Phase I lung cancer trial appeared first on Clinical Trials Arena.

Significant regulatory milestone:S.